Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Sinovac Applies to Begin Mumps Vaccine Trial

publication date: May 6, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Sinovac Biotech (北京科兴生物制品有限公司) said its subsidiary Sinovac Dalian, a JV formed in January 2010, has applied to the SFDA to begin clinical trials of a mumps vaccine. The application is the first from the JV and also the first live attenuated vaccine from Sinovac. Sinovac has vaccines for measles and rubella in the works, which it plans to combine into a measles, mumps, rubella (MMR) vaccine for government purchasing. More details...

Stock Symbol: (NSDQ: SVA)



Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners